H. R. 1298—10
(H) A description of the programs to be undertaken
to maximize United States contributions in the areas of
technical assistance, training (particularly of health care
workers and community-based leaders in affected sectors),
and research, including the promotion of research on vac-
cines and microbicides.
(I) An identification of the relevant executive branch
agencies that will be involved and the assignment of prior-
ities to those agencies.
(J) A description of the role of each relevant executive
branch agency and the types of programs that the agency
will be undertaking.
(K) A description of the mechanisms that will be uti-
lized to coordinate the efforts of the relevant executive
branch agencies, to avoid duplication of efforts, to enhance
on-site coordination efforts, and to ensure that each agency
undertakes programs primarily in those areas where the
agency has the greatest expertise, technical capabilities,
and potential for success.
(L) A description of the mechanisms that will be uti-
lized to ensure greater coordination between the United
States and foreign governments and international organiza-
tions including the Global Fund, UNAIDS, international
financial institutions, and private sector organizations.
(M) The level of resources that will be needed on an
annual basis and the manner in which those resources
would generally be allocated among the relevant executive
branch agencies.
(N) A description of the mechanisms to be established
for monitoring and evaluating programs, promoting
successful models, and for terminating unsuccessful pro-
grams.
(O) A description of the manner in which private, non-
governmental entities will factor into the United States
Government-led effort and a description of the type of
partnerships that will be created to maximize the capabili-
ties of these private sector entities and to leverage
resources.
(P) A description of the ways in which United States
leadership will be used to enhance the overall international
response to the HIV/AIDS pandemic and particularly to
heighten the engagement of the member states of the G–
8 and to strengthen key financial and coordination mecha-
nisms such as the Global Fund and UNAIDS.
(Q) A description of the manner in which the United
States strategy for combating HIV/AIDS relates to and
supports other United States assistance strategies in devel-
oping countries.
(R) A description of the programs to be carried out
under the strategy that are specifically targeted at women
and girls to educate them about the spread of HIV/AIDS.
(S) A description of efforts being made to address the
unique needs of families with children with respect to
HIV/AIDS, including efforts to preserve the family unit.
(T) An analysis of the emigration of critically important
medical and public health personnel, including physicians,
H. R. 1298—11
nurses, and supervisors from sub-Saharan African coun-
tries that are acutely impacted by HIV/AIDS, including
a description of the causes, effects, and the impact on
the stability of health infrastructures, as well as a summary
of incentives and programs that the United States could
provide, in concert with other private and public sector
partners and international organizations, to stabilize health
institutions by encouraging critical personnel to remain
in their home countries.
(U) A description of the specific strategies developed
to promote sustainability of HIV/AIDS pharmaceuticals
(including antiretrovirals) and the effects of drug resistance
on HIV/AIDS patients.
(V) A description of the specific strategies to ensure
that the extraordinary benefit of HIV/AIDS pharma-
ceuticals (especially antiretrovirals) are not diminished
through the illegal counterfeiting of pharmaceuticals and
black market sales of such pharmaceuticals.
(W) An analysis of the prevalence of Human Papilloma
Virus (HPV) in sub-Saharan Africa and the impact that
condom usage has upon the spread of HPV in sub-Saharan
Africa.
(c) STUDY; DISTRIBUTION OF RESOURCES.—
(1) STUDY.—Not later than 3 years after the date of the
enactment of this Act, the Institute of Medicine shall publish
findings comparing the success rates of the various programs
and methods used under the strategy described in subsection
(a) to reduce, prevent, and treat HIV/AIDS, tuberculosis, and
malaria.
(2) DISTRIBUTION OF RESOURCES.—In prioritizing the dis-
tribution of resources under the strategy described in subsection
(a), the President shall consider the findings published by the
Institute of Medicine under this subsection.
SEC. 102. HIV/AIDS RESPONSE COORDINATOR.
(a) ESTABLISHMENT
OF
POSITION.—Section 1 of the State
Department Basic Authorities Act of 1956 (22 U.S.C. 265(a)) is
amended—
(1) by redesignating subsection (f) as subsection (g); and
(2) by inserting after subsection (e) the following:
‘‘(f) HIV/AIDS RESPONSE COORDINATOR.—
‘‘(1) IN GENERAL.—There shall be established within the
Department of State in the immediate office of the Secretary
of State a Coordinator of United States Government Activities
to Combat HIV/AIDS Globally, who shall be appointed by the
President, by and with the advice and consent of the Senate.
The Coordinator shall report directly to the Secretary.
‘‘(2) AUTHORITIES AND DUTIES; DEFINITIONS.—
‘‘(A) AUTHORITIES.—The Coordinator, acting through
such nongovernmental organizations (including faith-based
and community-based organizations) and relevant execu-
tive branch agencies as may be necessary and appropriate
to effect the purposes of this section, is authorized—
‘‘(i) to operate internationally to carry out preven-
tion, care, treatment, support, capacity development,
and other activities for combatting HIV/AIDS;
H. R. 1298—12
‘‘(ii) to transfer and allocate funds to relevant
executive branch agencies; and
‘‘(iii) to provide grants to, and enter into contracts
with, nongovernmental organizations (including faith-
based and community-based organizations) to carry out
the purposes of section.
‘‘(B) DUTIES.—
‘‘(i) IN GENERAL.—The Coordinator shall have pri-
mary responsibility for the oversight and coordination
of all resources and international activities of the
United States Government to combat the HIV/AIDS
pandemic, including all programs, projects, and activi-
ties of the United States Government relating to the
HIV/AIDS pandemic under the United States Leader-
ship Against HIV/AIDS, Tuberculosis, and Malaria Act
of 2003 or any amendment made by that Act.
‘‘(ii) SPECIFIC DUTIES.—The duties of the Coordi-
nator shall specifically include the following:
‘‘(I) Ensuring program and policy coordination
among the relevant executive branch agencies and
nongovernmental 
organizations, 
including
auditing, monitoring, and evaluation of all such
programs.
‘‘(II) Ensuring that each relevant executive
branch agency undertakes programs primarily in
those areas where the agency has the greatest
expertise, technical capabilities, and potential for
success.
‘‘(III) Avoiding duplication of effort.
‘‘(IV) Ensuring coordination of relevant execu-
tive branch agency activities in the field.
‘‘(V) Pursuing coordination with other coun-
tries and international organizations.
‘‘(VI) Resolving policy, program, and funding
disputes among the relevant executive branch
agencies.
‘‘(VII) Directly approving all activities of the
United States (including funding) relating to
combatting HIV/AIDS in each of Botswana, Cote
d’Ivoire, Ethiopia, Guyana, Haiti, Kenya, Mozam-
bique, Namibia, Nigeria, Rwanda, South Africa,
Tanzania, Uganda, Zambia, and other countries
designated by the President, which other des-
ignated countries may include those countries in
which the United States is implementing HIV/
AIDS programs as of the date of the enactment
of the United States Leadership Against HIV/
AIDS, Tuberculosis, and Malaria Act of 2003.
‘‘(VIII) Establishing due diligence criteria for
all recipients of funds section and all activities
subject to the coordination and appropriate moni-
toring, evaluation, and audits carried out by the
Coordinator necessary to assess the measurable
outcomes of such activities.
‘‘(C) DEFINITIONS.—In this paragraph:
‘‘(i) AIDS.—The term ‘AIDS’ means acquired
immune deficiency syndrome.
H. R. 1298—13
‘‘(ii) HIV.—The term ‘HIV’ means the human
immunodeficiency virus, the pathogen that causes
AIDS.
‘‘(iii) HIV/AIDS.—The term ‘HIV/AIDS’ means,
with respect to an individual, an individual who is
infected with HIV or living with AIDS.
‘‘(iv) RELEVANT
EXECUTIVE
BRANCH
AGENCIES.—
The term ‘relevant executive branch agencies’ means
the Department of State, the United States Agency
for International Development, the Department of
Health and Human Services (including the Public
Health Service), and any other department or agency
of the United States that participates in international
HIV/AIDS activities pursuant to the authorities of such
department or agency or this Act.’’.
(b) RESOURCES.—Not later than 90 days after the date of enact-
ment of this Act, the President shall specify the necessary financial
and personnel resources, from funds appropriated pursuant to the
authorization of appropriations under section 401 for HIV/AIDS
assistance, that shall be assigned to and under the direct control
of the Coordinator of United States Government Activities to Com-
bat HIV/AIDS Globally to establish and maintain the duties and
supporting activities assigned to the Coordinator by this Act and
the amendments made by this Act.
(c) ESTABLISHMENT OF SEPARATE ACCOUNT.—There is estab-
lished in the general fund of the Treasury a separate account
which shall be known as the ‘‘Activities to Combat HIV/AIDS Glob-
ally Fund’’ and which shall be administered by the Coordinator
of United States Government Activities to Combat HIV/AIDS Glob-
ally. There shall be deposited into the Fund all amounts appro-
priated pursuant to the authorization of appropriations under sec-
tion 401 for HIV/AIDS assistance, except for amounts appropriated
for United States contributions to the Global Fund.
TITLE 
II—SUPPORT 
FOR 
MULTILAT-
ERAL FUNDS, PROGRAMS, AND PUB-
LIC-PRIVATE PARTNERSHIPS
SEC. 201. SENSE OF CONGRESS ON PUBLIC-PRIVATE PARTNERSHIPS.
(a) FINDINGS.—Congress makes the following findings:
(1) Innovative partnerships between governments and
organizations in the private sector (including foundations,
universities, corporations, faith-based and community-based
organizations, and other nongovernmental organizations) have
proliferated in recent years, particularly in the area of health.
(2) Public-private sector partnerships multiply local and
international capacities to strengthen the delivery of health
services in developing countries and to accelerate research for
vaccines and other pharmaceutical products that are essential
to combat infectious diseases decimating the populations of
these countries.
(3) These partnerships maximize the unique capabilities
of each sector while combining financial and other resources,
scientific knowledge, and expertise toward common goals which
neither the public nor the private sector can achieve alone.